UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 17, 2008
OraSure Technologies, Inc.
(Exact Name of Registrant as Specified in Charter)
| Delaware | 001-16537 | 36-4370966 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
| 220 East First Street Bethlehem, Pennsylvania |
18015-1360 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: 610-882-1820
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 – Regulation FD Disclosure.
On April 17, 2008, OraSure Technologies, Inc. issued a press release announcing the receipt of a complaint from Inverness Medical Innovations, Inc., Inverness Medical Switzerland GmbH and Church & Dwight, Co., Inc., alleging infringement of U.S. Patent No. 6,485,982. A copy of the press release is attached as Exhibit 99 to this Form 8-K and is incorporated herein by reference.
Item 9.01 – Financial Statements and Exhibits.
(d) Exhibits
| Exhibit |
Description | |
| 99 |
Press Release, dated April 17, 2008, announcing the receipt by OraSure Technologies, Inc. of a complaint from Inverness Medical Innovations, Inc., Inverness Medical Switzerland GmbH and Church & Dwight, Co., Inc., alleging infringement of U.S. Patent No. 6,485,982. |
Signatures
Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| ORASURE TECHNOLOGIES, INC. | ||||
| Date: April 17, 2008 | By: | /s/ Jack E. Jerrett | ||
| Jack E. Jerrett | ||||
| Senior Vice President, General Counsel and Secretary | ||||
Index to Exhibits
| Exhibit No. |
Description | |
| 99 |
Press Release, dated April 17, 2008, announcing the receipt by OraSure Technologies, Inc. of a complaint from Inverness Medical Innovations, Inc., Inverness Medical Switzerland GmbH and Church & Dwight, Co., Inc., alleging infringement of U.S. Patent No. 6,485,982. |
Exhibit 99
 |
| Company contact: |
| Ronald H. Spair |
| Chief Financial Officer |
| 610-882-1820 |
| Investorinfo@orasure.com |
| www.orasure.com |
ORASURE TECHNOLOGIES TO DEFEND PATENT INFRINGEMENT LAWSUIT
Bethlehem, PA (April 17, 2008) – OraSure Technologies, Inc. (NASDAQ: OSUR) announced that it has received a complaint from Inverness Medical Innovations, Inc. (AMEX: IMA), Inverness Medical Switzerland GmbH and Church & Dwight, Co., Inc. (NYSE: CHD), filed in the United States District Court for the District of New Jersey, alleging that the manufacture and sale of the Company’s OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test infringes U.S. Patent No. 6,485,982. OraSure Technologies believes that none of its products, including the OraQuick ADVANCE® Test, infringe the patent or other intellectual property rights of any party. The Company also believes that the asserted patent is invalid and intends to defend this lawsuit vigorously.
About OraSure Technologies
OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities.
OraSure Technologies is the leading supplier of oral-fluid collection devices and assays to the public health and life insurance markets for the detection of antibodies to HIV. In addition, the Company supplies oral-fluid testing solutions for drugs of abuse testing. For more information on the Company, please go to www.orasure.com.
# # #